Veriheal

APRIL 11, 2022

We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds. This means that U.S. The company initiated the first legal transfer (as deemed by federal law) to the U.S.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

AUGUST 21, 2019

The watchdog refused to allow its national health service to prescribe medical cannabis for children with severe epilepsy because there is “not enough evidence it works”, a decision which angered campaigners and parents who said their children will suffer as a result. The final guideline is expected to be published in November 2019.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

Veriheal

MARCH 23, 2023

The people of Japan, a country renowned for its sushi cuisine scene, iconic Mount Fuji, and eye-catching cherry blossom trees, may soon have access to legal medicinal marijuana for intractable diseases. On Tuesday, January 24, several legislative bills were unveiled by the Japanese government.

Legalization 66

Legalization Marijuana Clinical Trials Seed-To-Sale 66

MedicalJane

JUNE 29, 2018

The FDA announced in a press release on Monday that it had approved the “first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy.”. Use of CBD in seizure prevention is well-documented with research ; and now, after conducting its own trials, the FDA appears to agree.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Cannabis Law Report

DECEMBER 1, 2021

Because it can cross the blood-brain barrier and gain access to the central nervous system (CNS), MYMD-1 is also positioned to be a possible treatment for brain-related disorders. The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

MARCH 2, 2020

The UK government has eased import restrictions on medicinal cannabis, but has admitted it needs to do much more to improve access for patients. It will continue to engage with medical associations and patients to build evidence, using trials in the UK to accelerate our understanding of how medicinal cannabis can benefit patients.

Medicine 59

Medicine Research and Development Clinical Trials Patients 59

Cannabis Info

OCTOBER 11, 2019

Epidiolex is an epilepsy-fighting cannabis base drug produced by GW Prescription drugs. In Europe, there are round 50,000 young adults and children affected by one of many two signs of epilepsy. This approval is the fruits of a few years of dedication and collaboration between GW, physicians and the epilepsy neighborhood.

Business 45

Business Epilepsy Clinical Trials Treatment 45

The Cannigma

AUGUST 26, 2021

The country legalized medical cannabis in 2016, but patients in the country have long criticized the program as too restrictive, and access to cannabis-based medicines remains behind that of many other legal cannabis jurisdictions. This also means that the TGA has not accessed these medicines for their safety, quality, or effectiveness.

Legalization 52

Legalization Access Medicine Clinical Trials 52

CannaTech

SEPTEMBER 16, 2018

Doctors have remained integral parts of a patient’s cannabis journey through what is known as the Access to Cannabis for Medical Purposes Regulation (ACMPR) act. Shedding Stigma and Promoting Patient Access. Patient access also hinges on a doctor’s preconceived notions of cannabis.

Education 66

Education Medicine Clinical Trials Patients 66

Cannabis Law Report

AUGUST 19, 2019

Access to medicinal cannabis for patients was legalised in Australia in 2016, allowing doctors to request permission to prescribe from the Australian government. This is at least due to the difficulty and cost involved in accessing a legal prescription. Patient access pathways.

Medicine 45

Medicine Patients Clinical Trials Access 45

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

The therapeutic role of Cannabidiol in mental health may grow in the future as more states and local governments alter their existing cannabis laws and allow for the greater access and testing of cannabis for medical purposes.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Canna Care Docs

DECEMBER 16, 2020

The difference is that medical patients may have access to higher dosages, among other benefits depending on their state, and receive a higher level of service to match them with the best products for their symptoms. What conditions is medical marijuana helpful for? Chronic pain.

Chronic Pain 52

Chronic Pain Marijuana Clinical Trials Epilepsy 52

Cannabis Law Report

APRIL 10, 2019

MP Philippa Whitford (representing Central Ayrshire ), a doctor, called for more support for clinical trials so that doctors will be more willing to prescribe medical cannabis products: “That is quite scary for doctors, particularly as if it is an unlicensed drug, they have to sign a form to say that they accept personal liability.

Clinical Trials 51

Clinical Trials Epilepsy Medicine Research and Development 51

Puff Puff Post

JANUARY 1, 2020

As a result, medical usage now grows substantially now that doctors and hospitals have access to legal cannabis. Sativex is a cannabinoid medication prescribed to cancer patients and individuals suffering from epilepsy and other muscle disorders. Nabiximol is a cannnabis derived drug that exited clinical trials in Spain.

Treatment 64

Treatment Clinical Trials Research and Development Cannabinoids 64

Cannabis Law Report

NOVEMBER 23, 2021

Because it can cross the blood-brain barrier and gain access to the central nervous system (CNS), MYMD-1 is also positioned to be a possible treatment for brain-related disorders. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Puff Puff Post

JANUARY 1, 2020

As a result, medical usage now grows substantially now that doctors and hospitals have access to legal cannabis. Sativex is a cannabinoid medication prescribed to cancer patients and individuals suffering from epilepsy and other muscle disorders. Nabiximol is a cannnabis derived drug that exited clinical trials in Spain.

Treatment 40

Treatment Clinical Trials Research and Development Cannabinoids 40

Veriheal

AUGUST 31, 2020

Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

JANUARY 5, 2022

Because it can cross the blood-brain barrier and gain access to the central nervous system (CNS), MYMD-1 is also positioned to be a possible treatment for brain-related neurodegenerative and neuroinflammatory disorders. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

JANUARY 13, 2020

commercial and government payors to ensure that appropriate patients have access to Epidiolex with as few restrictions as possible. Nabiximols (known as “Sativex” outside US) in the US: Commence pivotal clinical program in initial target indication of spasticity associated with Multiple Sclerosis. Work with U.S.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

The Cannigma

JUNE 15, 2021

The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. For now, if you have access to quality CBD products, there’s no reason to prioritize CBG products. Shutterstock). It’s everywhere.

CBD 122

CBD Research and Development Epilepsy Extraction 122

MMJ Recs

DECEMBER 22, 2023

Studies have shown the efficacy of medical cannabis in treating conditions such as chronic pain, epilepsy, and certain mental health disorders. This shift can be attributed to increased access to information, a more liberal societal outlook, and a willingness to explore alternative healthcare options.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Cannabis Law Report

JULY 15, 2019

Law 33/2018 set the framework for the regulation of the use of cannabis-based medicinal products, preparations and substances that would effectively allow Portuguese patients to access medical cannabis What really has changed during the last year? The hardest part has already been done.

Medicine 40

Medicine Clinical Trials Patients Access 40

Cannabis Law Report

DECEMBER 7, 2021

This trend is also observed in the pediatric population, where MCs are authorized in children for refractory epilepsy, especially in Dravet syndrome and Lennox-Gastaut syndrome 2. For eligible publications with missing data, the corresponding author was contacted to access additional data.

Safety 52

Safety Cannabinoids Events Data 52

Greencamp

AUGUST 16, 2018

The CBD cannabinoid is proven to be an exceptional seizure-controlling agent for epilepsy patients, and also shows great promise for treating Parkinson’s , Alzheimer’s and Multiple Sclerosis. Marijuana and Epilepsy: Here’s How Cannabis Stops Seizures (12 Studies). Exploring the available research on ALS and cannabinoids.

Strains 94

Strains Cannabinoids Research and Development Indica 94

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Accessed July 25, 2021. Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JUNE 1, 2021

Steve Barbera to Vice President, Market Access. Prior to joining Sesen Bio, Mr. Barbera served as the Vice President of Market Access at UroGen Pharma and played a critical role in the launch of the company’s first commercial product, Jelmyto ®. Julie Hoff to Vice President, Human Resources.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Cannabis Law Report

JANUARY 20, 2022

Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines. Medicines and Healthcare products Regulatory Agency’s Innovative Licensing and Access Pathway (“ILAP”), offering the potential to accelerate time to market.

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

OCTOBER 26, 2019

One such circumstance is a clinical trial. A clinical trial in Australia must have an Australian sponsor (whether it be an individual (e.g., Two of the avenues for supply of UTGs for clinical trials are the Clinical Trial Exemption (CTX) Scheme and the Clinical Trial Notification (CTN) Scheme.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Cannabis Law Report

JANUARY 26, 2022

MAPS Public Benefit Corporation will coordinate trial design with Medicines and Healthcare products Regulatory Agency to create a road map for early patient access in the UK. No drug is without risks, so clinical trials have included careful investigation of possible adverse effects.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

CannaTech

SEPTEMBER 23, 2019

The acceptance of medical cannabis by clinicians, researchers and government bodies is fairly universal, and patients have benefited from widespread access to full-spectrum cannabis in flower and oil form. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Peninsula Alternative Health

MAY 15, 2019

Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. References Staff, T.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

MGC Pharma

FEBRUARY 20, 2018

CBD passes Stage 3 clinical trial for the treatment of epilepsy in children A study published last year in The New England Journal of Medicine saw scientists studying the effects of CBD on epileptic seizures in patients with Dravet syndrome, a severe epileptic disorder leading to frequent and uncontrollable seizures in children.

Research and Development 100

Research and Development Clinical Trials Patients Chronic Pain 100

Cannabis Law Report

JULY 12, 2019

As reported in the Guardian, Analytical Cannabis emphasises the importance of this for those suffering from conditions such as chronic pain, epilepsy and neurological and psychiatric disorders who have long been seeking access to what they hope is a transformative medicine.

Epilepsy 40

Epilepsy Medicine Clinical Trials Chronic Pain 40

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Patients can legally access medicinal cannabis through a doctor, via the TGA’s Authorised Prescribers and Special Access schemes.

Research and Development 52

Research and Development Medicine Access Media 52

The Cannigma

MAY 7, 2021

The Cannabis Enigma podcast is a co-production of The Cannigma and Americans for Safe Access. You’ve had this conversation in the US for over 20 years in some states so it’s not as if suddenly overnight, people have woken up to the discussion of cannabis and cannabis legalization and cannabis access. Music by Desca.

Supply Chain 120

Supply Chain Patients Access Hemp 120